Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Limited Stage Small Cell Lung Cancer

In brief

The goal of this clinical trial is to compare the efficacy and safety of trilaciclib versus placebo in subjects with limited stage small cell lung cancer. The main question it aims to answer is: Does trilaciclib have a myeloprotective effect in subject with limited stage small cell lung cancer? Participants will be randomised to receive either trilaciclib or placebo.

Key facts

Study ID

NCT07473128

Run by

Pharmacosmos A/S

People needed

120

Starts

2026-06-30

Expected to finish

2027-06-01

Last updated by the study team

2026-06-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of Limited-Stage Small Cell Lung Cancer
• Complete recovery from prior anti-tumor surgical procedures
• Measurable and evaluable disease through tumor assessment
• Willingness to participate and sign informed consent form

You may not qualify if…

• Extensive Stage Small Cell Lung Cancer
• Active cardiovascular disease
• Known hypersensitivity to trilaciclib, etoposide, carboplatin, cisplatin or any component in their formulations
• Pregnant or nursing women

Where it is running

• Pharmacosmos Investigational Site — Oakland, California, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.